Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Enterprise Value (2016 - 2025)

Historic Enterprise Value for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$256.9 million.

  • ImmunityBio's Enterprise Value fell 9856.39% to -$256.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.9 million, marking a year-over-year decrease of 9856.39%. This contributed to the annual value of -$148.8 million for FY2024, which is 4392.11% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Enterprise Value is -$256.9 million, which was down 9856.39% from -$152.7 million recorded in Q2 2025.
  • ImmunityBio's Enterprise Value's 5-year high stood at -$49.0 million during Q2 2023, with a 5-year trough of -$318.9 million in Q4 2021.
  • For the 5-year period, ImmunityBio's Enterprise Value averaged around -$148.6 million, with its median value being -$129.4 million (2024).
  • As far as peak fluctuations go, ImmunityBio's Enterprise Value skyrocketed by 6560.3% in 2022, and later crashed by 34260.62% in 2024.
  • ImmunityBio's Enterprise Value (Quarter) stood at -$318.9 million in 2021, then surged by 65.6% to -$109.7 million in 2022, then tumbled by 141.99% to -$265.4 million in 2023, then skyrocketed by 43.92% to -$148.8 million in 2024, then tumbled by 72.6% to -$256.9 million in 2025.
  • Its last three reported values are -$256.9 million in Q3 2025, -$152.7 million for Q2 2025, and -$60.6 million during Q1 2025.